Workflow
Blood Volume Analysis (BVA) technology
icon
Search documents
Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care
Globenewswire· 2025-09-04 12:00
Core Insights - The study published in the Journal of Critical Care reveals frequent inaccuracies in clinical assessments of fluid status in critically ill patients, particularly those with sepsis and COVID-19 [1][2] - Daxor Corporation's BVA technology is highlighted as a solution to improve fluid management in critical care settings, emphasizing the need for accurate blood volume measurement [4][5] Study Findings - A significant percentage of patients were misclassified during clinical assessments, with 48% of COVID-19 patients incorrectly deemed hypervolemic when they were actually hypovolemic [8] - The study indicates that the albumin transudation rate (ATR) was persistently elevated in both sepsis and COVID-19 patients, suggesting ongoing capillary leakage [8] - Sepsis patients exhibited a higher ATR compared to COVID-19 patients, indicating more severe endothelial dysfunction despite lower admission severity scores [8] Company Positioning - Daxor's FDA-approved BVA-100™ Analyzer was utilized in the study, showcasing its capability to provide objective measurements of total blood volume and ATR [4] - The company has received FDA clearance for a new rapid BVA system, which is three times faster than the BVA-100™ and maintains over 95% accuracy, addressing urgent diagnostic needs in critical care [5][6] - Daxor is positioned for revenue expansion in critical care medicine, supported by new data, funding opportunities, and advancements in its technology [6][9]
Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter
Globenewswire· 2025-09-02 12:00
Core Insights - Daxor Corporation has achieved significant milestones in 2025, including FDA clearance for a new rapid Blood Volume Analysis (BVA) system, marking a transformative moment for the company [4][8] - The company reported a 73% increase in unaudited revenues for the first half of 2025 compared to the same period in 2024, driven by sales of diagnostic kits and military contracts [6][8] - Daxor's net asset value increased to $36.6 million as of June 30, 2025, reflecting a $3.97 million increase from the previous year [6][8] Product Innovation - The new BVA system is three times faster, portable, and smaller than the existing BVA-100, while maintaining the ability to measure total blood volume, red blood cell volume, plasma volume, and albumin transudation rate [4][8] - The company is committed to rolling out the new BVA system and accelerating commercial operations alongside ongoing research and development for additional products [8] Financial Performance - Daxor's operating division reported a significant revenue increase, with net asset value per share rising to $7.15, up $0.40 from the previous year [6][8] - The company experienced a net decrease in unrealized appreciation on investments but reported net realized gains of $468,212 for the first half of 2025 [6] Market Adoption and Clinical Validation - The adoption of Daxor's BVA technology has accelerated, with new accounts contributing to revenue growth and clinical acceptance [6][8] - A significant study published in the American Heart Journal highlighted the utility of BVA technology in managing heart failure, showing that patients identified as euvolemic had 2.61 times better survival rates [9] Industry Engagement - Daxor actively engaged with the medical community through industry events to showcase its technology and foster awareness among cardiovascular professionals [7][9] - The company exhibited at major conferences, further solidifying its presence in the healthcare sector [9]